Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted EGFR TKI Induction and Concurrent Radiotherapy in Unresectable Stage III EGFR-Mutant NSCLC
ChiCTR2400092180Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Ruijin Hospital. Primary endpoint: 2-year progression-free survival rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400092180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092180.